[Form 4] CYTOKINETICS INC Insider Trading Activity

Rhea-AI Filing Summary

CYTOKINETICS, Inc. director Dr. Edward M. Kaye reported a sale of 6,757 shares of common stock on 10/06/2025 under a transaction coded S (sale). The filing shows the sale price as $60 per share and that Dr. Kaye beneficially owned 9,778 shares following the transaction. The form is signed by an attorney-in-fact and the reporting box indicates the trade was made pursuant to a Rule 10b5-1 plan.

Positive

• Transaction reported under a Rule 10b5-1 plan, which can reduce timing-related legal risk
• Filing discloses post-sale holdings (9,778 shares), providing transparency

Negative

• Director sold 6,757 shares, which is a reduction in insider ownership

Insights

Corporate Governance Analyst

Insider completed a planned sale under a 10b5-1 arrangement on 10/06/2025.

The reporting shows a director executed a sale of 6,757 shares at $60, reducing his direct beneficial holdings to 9,778 shares. The checked box for a Rule 10b5-1 plan indicates the transaction was intended to meet the affirmative-defense conditions of that rule.

This is a routine disclosure for insiders and typically reduces legal risk if the plan was established properly; investors may note the post-sale holding level and the sale price 10/06/2025 as a datapoint for insider activity over the near term.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/06/2025		S		6,757	D	$60	9,778	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John Faurescu, attorney-in-fact for Dr. Kaye	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CYTK insider Dr. Edward M. Kaye report on 10/06/2025?

He reported a sale of 6,757 shares of common stock at $60 per share on 10/06/2025.

Was the sale by the CYTK director part of a 10b5-1 trading plan?

Yes. The form indicates the transaction was made pursuant to a Rule 10b5-1(c) written plan.

How many CYTK shares does the reporting person own after the sale?

The filing shows 9,778 shares beneficially owned following the reported transaction.

Who signed the Form 4 for Dr. Kaye?

The form was signed by John Faurescu, attorney-in-fact, on 10/06/2025.

What transaction code was used on the Form 4?

The transaction is coded S, indicating a sale of securities.